Class 5 - Live Case from St Francis Hospital, New Jersey

Shockwave IVL
200 videos
Simplify your procedures with Intravascular Lithotripsy (IVL) by safely modifying intimal and medial calcium to achieve optimal outcomes while minimising trauma, complications and costs due to its...
Read More
Simplify your procedures with Intravascular Lithotripsy (IVL) by safely modifying intimal and medial calcium to achieve optimal outcomes while minimising trauma, complications and costs due to its unique MOA.
Prior to use, please reference the instructions for use and important safety information: https://shockwavemedical.com/important-safety-information-universal/
Discover more at ShockwaveIVL.com
Speakers
Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac...
Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.
James Spratt Professor of Interventional cardiology with a sub-speciality interest in complex PCI, intravascular...
James Spratt Professor of Interventional cardiology with a sub-speciality interest in complex PCI, intravascular imaging and CTO. He is widely published within this area and has performed live case demonstrations globally. He has an interest in medical education and is the Founder of Optima Education.
Dr Julian Strange is a consultant interventional cardiologist at Bristol Heart Institute, UK. His specialty and...
Dr Julian Strange is a consultant interventional cardiologist at Bristol Heart Institute, UK. His specialty and research interests are in coronary disease and include coronary angioplasty, complex PCI and chronic total occlusions (CTO) as well as advanced heart attack and cardiac arrest therapies.
Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in...
Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.
Start a conversation